Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic PLC

www.medtronic.com

Latest From Medtronic PLC

Federal Court Sides With IRS In Medtronic Transfer Tax Dispute

The 8th Circuit Court of Appeals has sent a Medtronic transfer pricing tax dispute back to US Tax Court after finding that the tax court verdict hadn’t addressed several relevant factors. IRS initially asked for $1.4bn in back taxes in the case.

Medical Device Regulation

Medicare Advisors Mostly Favor TAVR Center Volume Thresholds

The Medicare Evidence Development & Coverage Advisory Committee looked at the evidence for procedural volume requirements that hospitals and heart-team members currently must meet to perform transcatheter aortic valve replacements versus the prospect of quality measures as a condition of coverage. The discussion at a meeting held this week will inform the US Medicare agency's ongoing reconsideration of its TAVR coverage policy.

Advisory Committees Market Access

Market Intel: New Thermal Therapies Blaze Trail In Fast-Growing Cancer Ablation Market

Cancer rates are rising worldwide and as diagnostic techniques continue to improve, new surgical ablation devices are becoming crucial weapons in the growing arsenal of cancer treatment tools. These devices allow doctors to burn away tumors with precision, speed and safety, without the side-effects that patients undergoing radical cancer therapy often experience. This article provides an overview of the cancer ablation market, highlights the key players working on these devices and discusses their potential applications. It also includes critical insights from a leading interventional urologist on the pros and cons of using these various technologies in treating prostate cancer.

Cancer Surgical Procedures

Medtronic Agrees To Settle Infuse Shareholder Suit

Device manufacturer Medtronic has offered to pay $43m to resolve a lawsuit brought by shareholders. The suit, filed in 2013, claimed that the company defrauded investors via deceptive marketing for its Infuse bone graft product.

Medical Device Regenerative Medicine
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register